Search Results

MERLION Study Evaluates Early Outcomes of iVascular's Luminor DCB to Treat TASC C and D Tibial Disease

June 25, 2020—Professor Tjun Tang, MD, presented interim 6-month results from the MERLION study exploring the iVascular Luminor drug-coated balloon (DCB) in infrapopliteal atherosclerotic lesions in chronic limb threatening ischemia (CLTI) patients with a high incidence of diabetes mellitus (DM) and end-stage renal failure (ESRF).

MedAlliance’s SELUTION4BTK IDE Trial Begins Enrollment

June 8, 2022—MedAlliance announced that the first patient has been enrolled in the SELUTION4BTK trial.

MedAlliance Set to Begin SELUTION4BTK Randomized Trial of Its Selution SLR Sirolimus-Eluting Balloon

May 27, 2022—MedAlliance has announced receipt of FDA investigational device exemption (IDE) approval and its plans to begin enrollment in SELUTION4BTK, a randomized controlled trial evaluating the safety and efficacy of the company's Selution SLR sirolimus-eluting balloon in below-the-knee (BTK) peripheral artery disease.

MedAlliance’s Selution SLR Studied for Complex BTK Disease at 24 Months in PRESTIGE

November 4, 2022—The PRESTIGE study investigated the performance outcomes and safety of Selution SLR, a sustained limus release sirolimus-eluting balloon (MedAlliance SA) for the treatment of TASC II C and D tibial occlusive lesions in patients with chronic limb-threatening ischemia (CLTI).

MedAlliance’s Selution SLR Sirolimus-Eluting Balloon Studied in PRESTIGE for Treatment of CLTI

October 6, 2021—Eighteen-month results were revealed from the PRESTIGE study that investigated performance outcomes and the safety profile of MedAlliance’s Selution sustained limus release (SLR) sirolimus-eluting balloon for treatment of TransAtlantic Inter-Society Consensus (TASC) II C and D tibial occlusive lesions in patients with chronic limb-threatening ischemia (CLTI).

ISABELLA Evaluates MedAlliance's Selution SLR for Treatment of Failing AV Fistulas in Hemodialysis Patients

November 24, 2020—MedAlliance announced completion of patient enrollment in the ISABELLA clinical trial at Singapore General Hospital (SGH).

Enrollment Begins for MedAlliance’s PRISTINE Registry of the Selution SLR Sirolimus-Eluting Balloon

October 12, 2020—MedAlliance announced that the first two patients have been enrolled in the PRISTINE registry, which is evaluating the company’s Selution SLR (sustained limus release) sirolimus drug-eluting balloon for the treatment of patients with chronic limb-threatening ischemia (CLTI).

Enrollment Completed in PRESTIGE BTK Trial of MedAlliance’s Selution SLR Device

January 10, 2020—MedAlliance announced the completion of patient enrollment in the PRESTIGE below-the-knee clinical trial, which is evaluating the 6-month safety and performance outcomes of the company’s Selution SLR sirolimus-eluting balloon catheter for the treatment of long tibial occlusive lesions (TASC C & D) in patients with critical limb ischemia.

12-Month Data Presented for MedAlliance’s Selution SLR in BTK Lesions

January 28, 2021—MedAlliance announced that 12-month results from the PRESTIGE below-the-knee (BTK) study were presented as a late-breaking trial at LINC 2021, the Leipzig Interventional Course held as a virtual event January 25-29.

1-Year Data Presented From MERLION Trial of iVascular’s Luminor DCB in BTK Treatment

February 4, 2021—iVascular announced new evidence from the MERLION trial of the company’s Luminor drug-coated balloon (DCB) to treat complex below-the-knee (BTK) lesions.

MedAlliance’s Selution SLR Continues to Be Evaluated to Treat BTK Disease in PRISTINE Registry

August 12, 2021—MedAlliance, which is headquartered in Switzerland, announced completion of patient enrollment in the PRISTINE clinical trial with the company’s Selution SLR 018 sirolimus drug-eluting balloon (DEB) with sustained limus release for the treatment of patients with below-the-knee (BTK) disease.

FDA Grants Breakthrough Device Designation for Concept Medical's MagicTouch AVF Sirolimus-Coated Balloon

August 29, 2019—​​​​​​Concept Medical Inc. announced that it has been granted FDA Breakthrough Device designation for the company's MagicTouch arteriovenous fistula (AVF) sirolimus-coated balloon (SCB) catheter for the treatment of stenotic lesions of AVFs or AV grafts (AVGs) in hemodialysis treatment of renal failure.

Neuroform, Enterprise, and LVIS Self-Expanding Stents Compared for Treating Cerebral Aneurysms

November 21, 2017—A study by Jun Wang, MD, et al compared the clinical and angiographic outcomes of treating cerebral aneurysms with three self-expanding nitinol stents: Neuroform (Stryker), Enterprise (Codman Neuro), and Low-profile Visualized Intraluminal Support stents (LVIS/LVIS Jr; MicroVention Terumo).